IFPMA

STATEMENT

Innovative pharmaceutical industry supports effective implementation of the Global Framework on Chemicals

16 NOVEMBER 2026, GENEVA - Recognizing that environmental sustainability and public health are intrinsically linked, the innovative pharmaceutical industry has long contributed to responsible chemicals and waste management across the value chain and supports the objectives of the Global Framework on Chemicals (GFC). Our industry remains ready to contribute scientific, technical, and operational expertise to its effective implementation while continuing to advance the development and delivery of medicines and vaccines for people worldwide.

Chemicals are essential to the research, development, manufacture, and delivery of medicines and vaccines, and their safe and responsible management is fundamental to protecting human health and the environment. Collectively, we must also safeguard patient safety and product quality, maintain uninterrupted supply and timely access to medicines and vaccines, and enable continued innovation.

To achieve our collective goals, implementation of the GFC should be science-based and proportionate to risk, considering hazard, exposure, and conditions of use. By building upon existing rigorous pharmaceutical, chemicals, occupational safety, and environmental regulatory frameworks, stakeholders can advance safer and more sustainable alternatives where they are technically feasible, scalable, and compatible with strict product efficacy and safety requirements. Governments and stakeholders should establish predictable requirements, realistic transition pathways, and appropriate flexibility for critical healthcare uses, ensuring that environmental progress reinforces – rather than compromises – global healthcare resilience.

IFPMA member companies invest in responsible and sustainable chemicals management across the value chain – from research, development, and sourcing to manufacturing, product use, and end-of-life management – while meeting robust health and environmental regulatory requirements. In so doing, we should recognize the distinct characteristics and requirements of the key phases involved in developing and delivering new and innovative medicines to patients: (a) research and development, (b) sourcing and manufacturing, and (c) product use and end-of-life management.

Building on longstanding engagement with governments, regulators, health and environmental authorities, international organizations, academia, and other stakeholders, the innovative pharmaceutical industry looks forward to contributing expertise, practical solutions, and good practices to advance the GFC objectives and support sustainable healthcare systems. IFPMA calls for continued

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org
ifpma.org

@IFPMA
/IFPMA

collaboration among stakeholders to deliver coherent, practical, and risk-proportionate implementation that delivers benefits for people and the environment.

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org
ifpma.org

@IFPMA
/IFPMA